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Abstract
A dramatic rise in the incidence of obesity in the U.S. has accelerated the search for interventions
that may impact this epidemic. One recently recognized target for such intervention is adipose
tissue, which secretes a variety of bioactive substances including prostaglandins. Prostaglandin E2
(PGE2) has been shown to decrease lipolysis in adipocytes, but limited studies have explored
alternative mechanisms by which PGE2 might impact obesity, such as adipogenesis or lipogenesis.
Studies conducted on ApcMin/+ mice indicated that selective inhibition of the cyclooxygenase
(COX)-2 enzyme led to significant reductions in fatty acid synthase (FAS) activity in adipose tissue
suggesting lipogenic effects of PGE2. To further investigate whether these lipid mediators directly
regulate lipogenesis, we used 3T3-L1 adipocytes to determine the impact of eicosapentaenoic acid
(EPA) and celecoxib on PGE2 formation and FAS used as a lipogenic marker. Both arachidonic acid
(AA) and EPA dose-dependently increased PGE secretion from adipocytes. AA was expectedly
more potent and exhibiting at 150 uM dose a 5-fold increase in PGE2 secretion over EPA. Despite
higher secretion of PGE by EPA and AA compared to control, neither PUFA significantly altered
FAS activity. By contrast both AA and EPA significantly decreased FAS mRNA levels. Addition of
celecoxib, a selective COX-2 inhibitor, significantly decreased PGE2 secretion (p < 0.05) versus
control, and also significantly decreased FAS activity (p < 0.05). Unexpectedly, the combination of
exogenous PGE2 and celecoxib further decreased the FAS activity compared to PGE2 alone or
untreated controls. In conclusion, EPA-mediated inhibition of AA metabolism did not significantly
alter FAS activity while both AA and EPA significantly decreased FAS mRNA expression. COX-2
inhibition significantly decreased PGE2 production resulting in a decrease in FAS activity and
expression that was not reversed with the addition of exogenous PGE2, suggesting an additional
mechanism that is independent of COX-2.
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Background
Several bioactive molecules and hormones have been
reported to be secreted by adipose tissue [1,2]. Related to
our current work, the secretion of prostaglandins such as
prostaglandin E2 (PGE2) has been shown in human and
rodent adipocytes [3-7]. Further, the presence of prostag-
landin E receptors (EP1–4) in these tissues as well [8-10]
has led to research into a possible autocrine or paracrine
role for this Arachidonic Acid (AA) metabolite. Several
studies reported antilipolytic roles for PGE2 in cultured
adipocytes and adipose tissue explants [11-13], most
likely acting through a G-inhibitory protein-coupled EP3
receptor [14], confirming a paracrine/autocrine role of
PGE2 in adipocytes. Additional roles for PGE2 in adi-
pocytes include increased secretion of leptin release from
mouse adipose tissue [15] and decreased hepatic lipo-
genic gene expression [16]. These studies did not, how-
ever, address whether PGE2 also exerts lipogenic or
adipogenic effects in adipocytes.
Several studies have explored regulation of hepatic lipo-
genesis by polyunsaturated fatty acids (PUFA) [17,18].
However, these effects may be tissue specific as hepatic
and adipose lipogenesis may be differentially regulated
[19]. Arachidonic acid (AA, 20:4 n-6) has been shown to
stimulate glucose intake in adipocytes by increasing glu-
cose receptor levels in the cell membranes [20] potentially
increasing substrate availability for de novo lipogenesis.
AA is also the preferential substrate for the cyclooxygenase
(COX) enzymes, resulting in production of PG and other
metabolites [21,22]. In mature adipocytes, PGE2 is the pri-
mary PG produced from the COX pathway [23-26].
In most cases, AA and dietary eicosapentaenoic acid (EPA,
20:5 n-3) exert opposing effects; however, hepatic lipo-
genesis is downregulated by both fatty acids [16,27,28].
EPA impacts adipocyte biological functions via two dis-
tinct mechanisms. The first is via transcriptional activa-
tion of lipogenic and adipogenic genes by binding to
nuclear receptors such as PPARgamma. The second mech-
anism is via direct competition with AA for incorporation
into membrane phospholipids and subsequent conver-
sion to eicosanoids including PGs. While the first mecha-
nism has been extensively studied, few studies have
addressed the second mechanism in adipocytes. Synthe-
sized or preformed AA is incorporated into the sn-2 posi-
tion of cell membrane phospholipids and subsequently
liberated by phospholipases (cPLA2). COX metabolizes
AA into PGE2, which is then secreted by the cell to act in
an autocrine/paracrine fashion via specific EP receptors.
EPA competes with AA for incorporation into cell mem-
brane phospholipids and for the active site on the COX
enzymes when cPLA2 is activated. This competition and
the resulting production of PGE3 when COX metabolizes
EPA, could result in decreased levels of PGE2.
Decreased PGs production, and particularly PGE2, by
COX-2 inhibitors has been demonstrated in adipocytes
[4,29-31]. Further, initial in vivo studies demonstrated
that inhibition of PGE2 synthesis decreased FAS activity in
mouse adipose tissue and this was largely reversed by co-
treatment with PGE2 receptor agonist. We hypothesized
that these effects reflected direct actions of PGE2 (or its
modulators, PUFA or COX ligands) on adipose tissue.
Specifically we tested whether manipulation of PGE2 lev-
els by addition of EPA (dietary intervention) or selective
COX-2 inhibition (pharmaceutical intervention)
decreases PGE2 production from adipocytes and subse-
quently downregulates FAS enzyme activity. If AA and
EPA modulate FAS activity or expression via changes in
PGE2 levels, it is then expected that these fatty acids exert
opposite effects on FAS expression. We performed a series
of experiments in cultured adipocytes which provide com-
pelling evidence that PUFA effects on adipose tissue FAS
were independent of changes in PGE levels.
Materials and methods
Experiment Design
Animal Experiments
Male C57BL/6J ApcMin/+ mice (Jackson Labs, Bar Harbor,
ME) were obtained at 4–6 weeks of age. Mice were housed
in a temperature-controlled room with 14 h periods of
light and 10 h periods of darkness and given free access to
food and water. The health of the animals was checked
daily. Food was withheld overnight prior to sacrifice. All
animal procedures were approved by the University of
Tennessee Animal Care and Use Committee. Mice were
fed a purified AIN-93G powder diet (Dyets, Inc., Bethle-
hem, PA). Diets containing drug treatments were prepared
daily by thoroughly mixing the drugs with the AIN-93G
diet to achieve desired drug dosage. Diets were stored at -
20°C and all animals were provided fresh food daily.
Food consumption was monitored daily and body
weights were recorded weekly.
We used the C57BL/6J ApcMin/+ mice which we have previ-
ously shown to be highly responsive to pharmacological
and dietary manipulations of PGE2 [32,33]. The experi-
mental design we used has been previously described
[32]. Briefly, male C57BL/6J ApcMin/+ mice were main-
tained on the AIN-93G diet until approximately 80 days
of age at which time they were randomly assigned to treat-
ment groups consisting of control, E-prostaglandin recep-
tor agonists (EPR-A) [16,16-dimethyl-PGE2 and 17-
phenyl-trinor PGE2 (Cayman Chemical, Ann Arbor, MI),
10 μg each], COX inhibitor (piroxicam [Sigma, St. Louis,
MO], 0.5 mg/mouse/day), or piroxicam + EPR-A. The
mice were sacrificed at 11–12 weeks of age and epididy-
mal adipose tissue was harvested, weighed, snap frozen in
liquid nitrogen and stored at -80°C until further analysis.
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Cell Culture Experiments
3T3-L1 preadipose cells were purchased from American
Type Culture Collection (ATCC, Rockville, MD) and were
grown in 100 mm dishes. Culture medium was composed
of Dulbecco's modified Eagle's medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS) and 1% peni-
cillin/streptomycin (P/S). Cells were plated on day 1
(~200,000 cells/100 mm dish) and grown for 3–4 days to
confluence. At confluence, media was changed and sup-
plemented with 250 nM Dex, 0.5 mM Mix, and 10 nM
insulin for 48 h to induce adipocyte differentiation, after
which cells were cultured with regular media supple-
mented with insulin. Differentiation was considered com-
plete at 5–7 days post-confluence. Twenty-four hours
prior to treatment, regular media was replaced with star-
vation media consisting of DMEM, P/S, and 1% fatty acid-
free bovine serum albumin (BSA). Treatment media con-
sisted of starvation media + 10 nM insulin and individual
(FA or inhibitor) treatments. Because fatty acids are pri-
marily found in the circulation as bound to albumin and
numerous studies have used this form of the fatty acid for
cell culture studies [34,35], all fatty acids in our experi-
ments were conjugated with BSA prior to the treatment.
Fatty acids were diluted in DMSO, added to the treatment
media and incubated in a shaking water bath for 2 hours
at 37°C to facilitate this binding. All treatments lasted 48
hours. Fatty acids were purchased from Nu-Check Prep,
Inc., Elysian, MN. All studies were conducted in cells that
were at least 80–95% differentiated as assessed by lipid
accumulation to insure findings are attributed to differen-
tiated rather than undifferentiated fat cells. Detailed
experimentation is described below:
Dose response studies for AA and EPA on PGE2
Dose response studies were conducted to determine phys-
iological EPA dose that would significantly reduce PGE2
levels when compared to an equivalent concentration of
AA. 3T3-L1 adipocytes were treated with AA or EPA (Nu-
Check Prep, Inc., Elysian, MN) in 25, 50, 100, 200, and
500 μM doses. Stock solutions of fatty acids were prepared
in dimethyl sulfoxide (DMSO). Treatment time was 48 h
for all doses. Cell culture media was collected to measure
secreted PGE2 levels and cells were harvested to prepare
cytosolic extracts used to measure FAS activity.
Effects of COX inhibition and various fatty acids and PGE2 on FAS
To determine whether treatment of adipocytes with EPA
reduces PGE2 production by reducing COX enzyme activ-
ity, cells were treated with EPA (50 μM and 150 μM),
COX-2 inhibitor (celecoxib or CI, 5 μM) (Pharmacia, St.
Louis, MO), and a combination of EPA (150 μM) + CI (5
μM). In addition, as a positive control for fat peroxida-
tion, EPA at 150 uM was also added alone to culture
media without cells. Treatments lasted 48 hrs, and cell cul-
ture media were then collected to measure PGE2 levels and
cells were harvested for cytosolic extracts. In a second set
of experiments, cell cultures were treated with vehicle
(DMSO), CI (1 μM), oleic acid (OA, 18:1 n-9), EPA, AA
(150 μM each treatment) or AA + EPA (75 μM each fatty
acid); media was removed from each dish, and cell cul-
tures were harvested for cytosolic extracts or total RNA.
Effect of PGE2 supplementation on FAS
To confirm that PGE2 was responsible for the decrease in
FAS activity seen with selective COX-2 suppression, PGE2
was added back to mean levels measured in the control
groups of previous experiments. 3T3-L1 cell cultures were
treated with vehicle (DMSO), CI (1 μM), PGE2 (300 pM)
(Cayman Chemical, Ann Arbor, MI), and CI + PGE2. 48
hours following treatment, two mL of media was removed
from each dish, and cells were harvested for cytosolic
extracts or total RNA.
FAS assay
The activity of FAS was determined in cytosolic extracts
from mouse adipose tissue and cell culture by measuring
the rate of oxidation of NADPH as previously described
[36]. Briefly, mouse adipose tissue collected from experi-
ment 1 was homogenized on ice in 500 μL of sucrose
buffer (pH 7.4). Cell culture plates harvested for cytosolic
extracts were washed twice in Hank's balanced salt solu-
tion, and then scraped using 350 μL of sucrose buffer. Cell
homogenates were sonicated on ice for 5 seconds. Tissue
and cell culture homogenates were centrifuged for 1 h
(12,000 × g) at 4°C. The supernatant was then removed
for analysis of FAS activity and protein concentration.
Protein assay
Protein concentration was determined in cytosolic
extracts by the method of Bradford [37], using Coomassie
blue reagent (Bio-Rad, Melville, NY). Each sample was
measured in duplicate using 10 μL of sample and 200 μL
of dye in a 96-well plate. After addition of the dye, the
samples were incubated for 5 minutes and read in a spec-
trophotometer at 590 nm. A standard curve was plotted
using serial dilutions of a BSA standard of known concen-
tration and sample concentrations were extrapolated
based on this standard curve.
PGE2 assay
Cell culture PGE2 concentrations were determined using
culture media samples obtained immediately prior to cell
harvest. PGE2 levels were measured by enzyme immu-
noassay (EIA) using the Correlate-EIA PGE2 Kit (Assay
Designs, Ann Arbor, MI) according to the manufacturer's
instructions. A standard curve was plotted using serial
dilutions of a known concentration of PGE2 and sample
concentrations were extrapolated based on this standard
curve. PGE2 EIA assay cross- reactivity for PGE3 is reported
by the manufacturer to be 16.3%.
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Real time RT-PCR
Real time RT-PCR was used to determine FAS mRNA
expression. Cells harvested for total RNA were scraped in
350 μL of Qiazol lysis reagent (Qiagen, Valencia, CA) and
sonicated on ice for 5 seconds. RNA was extracted using
the RNeasy™ lipid tissue midi kit (Qiagen) following the
manufacturer's protocol. RNA was stored at -80°C for use
in real time RT-PCR. Two micrograms of RNA was used to
synthesize cDNA. The FAS primers were ordered from Inv-
itrogen (Carlsbad, CA). The sequence of the forward
primer was 5'CCCAGAGGCTTGTGCTGACT 3' and the
sequence of the reverse primer was 5'CGAATGTGCTT-
GGCTTGGT 3'. The probe was ordered from Biosearch
Technologies, Inc. (Novato, CA). The sequence of the
probe was 5'(TET)CCGATCTGGAATCCGCAC-
CGG(TAMRA) 3'. TET is the quencher dye that inhibits the
fluorescence of the reporter dye when in close proximity.
TAMRA is the reporter dye and is measured at a wave-
length of 580 nm. The reactions were performed using the
SmartCycler SC1000-1 (one cycle each at 48°C * 1,800
sec and 95°C * 600 sec followed by 40 cycles at 95°C *
15 sec and 60°C * 60 sec) and analysed using SmartCycler
software (Cepheid, Sunnyvale, CA).
Statistical analysis
Statistical analysis for all assays was conducted using SPSS
(SPSS for windows, version 12.0, SPSS Inc., Chicago, IL).
Data were analyzed for homogeneity of variance and for
significant F-ratios between treatment groups using one-
way analysis of variance (ANOVA). Post-hoc analysis was
conducted using the Bonferroni (equal variance) or Dun-
nett's T3 (unequal variance) test when significant differ-
ences were detected. All values are expressed as mean +
SEM. Values of p < 0.05 were considered statistically sig-
nificant except where otherwise noted.
Results
Effect of COX inhibition and EP receptor agonists on FAS 
activity in mouse adipose tissue
Several studies including ours have previously shown that
inhibition of the cyclooxygenase enzymes decrease pros-
taglandin levels and tumor load in the ApcMin/+ mouse
model and that these effects can be reversed by addition
of prostaglandin E2 [32]. To determine whether this inhi-
bition also affects fat synthesis, and specifically whether a
lipogenic enzyme, FAS, is regulated by prostaglandin lev-
els, adipose tissue from mice treated with vehicle, COX
enzymes inhibitor piroxicam and/or EP receptor agonists
were studied. As shown in Fig 1, piroxicam significantly
decreased FAS activity (4-fold reduction, p < 0.01); similar
effects were obtained with another COX inhibitor, sulin-
dac (Data not shown). Combined piroxicam + EP receptor
agonists treatments resulted in significant partial restora-
tion of FAS activity (p < 0.02). Treatment with EP receptor
agonists alone also resulted in a significant reduction in
FAS activity when compared to control (p < 0.02).
Dose-Response effect of EPA and AA on PGE2 secretion 
and FAS activity in 3T3-L1 adipocytes
Consistent with studies that have shown the displacement
of AA by EPA in tissue phospholipids [33,38-40], the lev-
els of PGE2 were significantly lower when EPA was added
to the cell culture media compared to equivalent concen-
trations of AA (Fig. 2). As expected, addition of AA led to
a powerful dose-dependent increase in PGE2 production.
The two highest doses of EPA (200 μM and 500 μM)
resulted in PGE2 levels that were significantly higher than
control (p < 0.03), although this is most likely attributed
to the formation of PGE3[39,41]. However, at the doses
tested above, FAS enzyme activity did not exhibit any sig-
nificant changes from control, following AA or EPA treat-
ments except for AA at 500 μM (p < 0.03) which was
significantly higher than control (data not shown).
Effect of EPA versus COX inhibition (CI) on PGE levels in 
3T3-L1 adipocytes
Antagonistic effects of EPA and AA have been extensively
studied and reported and in most cases, EPA effects mimic
effects of COX inhibition. Increasing doses of EPA as
Effects of piroxicam and PGE2 receptor agonists onadipose FAS activity in ApcMin/+ miceigure 1
Effects of piroxicam and PGE2 receptor agonists ona-
dipose FAS activity in ApcMin/+ mice. Male C57BL/6J Apc-
Min/+ mice were maintained on the AIN-93G diet until 
approximately 80 days of age at which time they were ran-
domly assigned to treatment groups. Treatments consisted 
of control, piroxicam (0.5 mg/mouse/day), EPR-A (16,16-
dimethyl-PGE2 and 17-phenyl-trinor PGE2 -10 μg each), or 
piroxicam + EPR-A. Mice were sacrificed after 6 days of 
treatment and epididymal adipose tissue was harvested and 
snap frozen in liquid nitrogen. Tissue was homogenized in 
sucrose buffer and cytosolic extracts were analyzed for FAS 
activity using an activity assay as described in Materials and 
Methods. For treatments C and P + EPR-A n = 6; for P and 
EPR-A n = 5. Results represent the mean ± SEM. Values 
labeled with different letters are significantly different (p < 
0.05). Values with the same letters do not differ significantly.
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reported in Fig. 2 led to increased PGE2 levels, presumably
due to the formation of PGE3 (41) as the antibody had a
weak cross reactivity of PGE3 with the PGE2. Addition of
CI + EPA (150 μM) led to a significant reduction in PGE2
(p < 0.01) (Fig. 3), indicating that the PGE formation is
for the most part an enzymatic process. Addition of EPA
in the absence of cultured cells led to extremely low levels
of PGE confirming that the observed effects were not a
consequence of non-specific lipid peroxidation and that
increased PGE2 levels measured in EPA treated cell cul-
tures, supporting the likelihood of PGE3 formation, which
is detectable with the PGE2 immunoassay used. Our data
consistently show that the PGE2 formation is an enzy-
matic process, and since no exogenous AA was added to
the cells these data collectively support the idea that pro-
duction of PGE3 is responsible for the increases seen in
measured PGE2 production versus control.
Effect of selective COX-2 inhibition and different fatty
acids on PGE2 levels, FAS activity and FAS mRNA levels in
3T3-L1 adipocytes
As shown above, AA significantly increased PGE2 levels in
3T3-adipocytes and to a lesser extent, EPA also increased
PGE levels. PGE2 levels were effectively reduced compared
to control by the addition of CI (p < 0.001). All fatty acid
treatments resulted in measured increases in concentra-
tions of PGE compared to control, with responsiveness
increasing in the order of OA (p < 0.05), < EPA < AA + EPA
< AA (all p < 0.001) (Fig. 4A). Consistent with the
decrease in PGE2 levels by CI, FAS enzyme activity was sig-
nificantly decreased by COX inhibition (p < 0.05); how-
ever, EPA and OA exhibited only trends in decreasing FAS
activity without reaching statistical significance (Fig. 4B).
Expression of FAS mRNA showed significant changes with
COX inhibition and with AA and EPA treatment com-
pared to control (p < 0.05) (Fig. 5). The level of reduction
of FAS mRNA by the FA treatments correlated well with
the degree of unsaturation and chain length and may
therefore reflect a non-specific PUFA effect as previously
reported for PUFA effects on hepatic lipogenic genes
[42,43].
Dose-response effects of AA and EPA on PGE2 levels in 3T3-L1 adipocytesFigure 2
Dose-response effects of AA and EPA on PGE2 levels 
in 3T3-L1 adipocytes. 3T3 L-1 adipocytes were grown 6–7 
days post-confluence, and starved for 24 h in serum-free 
media containing FA-free BSA. Fatty acids were incubated in 
media containing FA-free BSA for two hours at 37°C in a 
shaking water bath prior to treatment. Treatment consisted 
of AA and EPA at 25, 50, 100, 200, and 500 μM concentra-
tions. After 48 hours, media was removed and stored at -
80°C until PGE2 levels were measured as described in the 
Materials and Methods. For treatments AA/EPA 500 n = 5; 
control (C) and AA/EPA 25 n = 10; AA/EPA 50, 100, 200 n = 
15. Values labeled with different letters are significantly dif-
ferent (p < 0.05). Results represent the mean ± SEM. Values 
with the same letters do not differ significantly.
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Effects of EPA and COX-2 inhibition on secreted PGE2 levels from 3T3-L1 adipocytesFigure 
Effects of EPA and COX-2 inhibition on secreted 
PGE2 levels from 3T3-L1 adipocytes. 3T3 L-1 adipocytes 
were grown 6–7 days post-confluence, and starved for 24 h 
in serum-free media containing FA-free BSA. Fatty acids were 
incubated in media containing FA-free BSA for two hours at 
37°C in a shaking water bath prior to treatment. Treatment 
consisted of EPA (50 and 150 μM), EPA (150 μM) + CI (5 
μM), CI (5 μM) and EPA (150 μM) in media without cells. 
After 48 hours, 2 mL of media was removed and stored at -
80°C. Media PGE2 levels were analyzed using EIA as 
described in the Materials and Methods. Results represent 
the mean ± SEM with a number of treatments n = 3–4. Val-
ues labeled with different letters are significantly different (p 
< 0.05). Values with the same letters do not differ signifi-
cantly. * Denotes culture media exposed to cell culture con-
ditions without cells.
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Effect of exogenously added PGE2 on selective COX-2 
inhibition of endogenous PGE2 secretion, FAS activity, and 
FAS mRNA levels in 3T3-L1 adipocytes
As demonstrated in our previous experiments, addition of
CI resulted in a significant decrease in PGE2 production (p
< 0.04). Addition of PGE2 to cells treated with CI restored
PGE2 levels and resulted in significantly higher levels ver-
sus CI treatment alone or versus control (p < 0.02) (Fig.
6A). Addition of PGE2 to cultures without CI resulted in
the expected significant increases of PGE2 over control lev-
els (p < 0.02). The level of PGE2 added was based on the
mean of previously measured levels of PGE2 secreted by
3T3-L1 control groups (300 pM). Analysis of FAS enzyme
activity and mRNA expression, however, produced unex-
pected results regarding CI and PGE2 interactions. Treat-
ment with CI resulted in a consistent decrease in FAS
enzyme activity while combined CI and exogenous PGE2
resulted in a significant and further decrease in FAS activ-
ity (p < 0.03) rather than the hypothesized reversal of CI
inhibition by PGE2 (Fig. 6B). Similar effects were also
observed on FAS mRNA (not shown). Addition of PGE2
alone, in the absence of CI, exerted no significant changes
on FAS.
Discussion
We and others have previously shown that adipocytes
secrete significant amounts of prostaglandins [3-7,30].
Further, it is well established that PGE2 decreases lipolysis
in adipocytes [11-14]. Our current study addressed
whether PGE2 also induces lipogenic activities in adi-
pocytes, which could further enhance their hypertrophic
effects in these cells. We have previously reported respon-
siveness of the ApcMin/+ mice to changes in prostaglandin
levels [35]. In this study we tested whether changes in
prostaglandins modulated fatty acid synthesis in adipose
tissue of these mice. We demonstrated that inhibition of
Effects of COX-2 inhibition and EPA addition on PGE2 levels (4A) and FAS activity (4B)Figure 4
Effects of COX-2 inhibition and EPA addition on 
PGE2 levels (4A) and FAS activity (4B). 3T3 L-1 adi-
pocytes were grown 6–7 days post-confluence, and starved 
for 24 h in serum-free media containing FA-free BSA. Fatty 
acids were incubated in media containing FA-free BSA for 
two hours at 37°C in a shaking water bath prior to treat-
ment. Treatment consisted of CI (1 μM), OA, EPA, AA (150 
μM each treatment), and AA + EPA (75 μM each FA). After 
48 hours, 2 mL of media was removed, and cells were 
scraped using 350 μL of sucrose buffer, sonicated, and centri-
fuged for 1 hour. Media and cytosolic extracts were stored at 
-80°C. Media PGE2 levels and FAS activity were measured as 
described in the Materials and Methods. For all treatments n 
= 10. Results represent the mean ± SEM. Values labeled with 
different letters are significantly different (p < 0.05). Values 
with the same letters do not differ significantly.
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Effects of n3 and n6 PUFA and COX-2 inhibition on 
FAS mRNA expression. 3T3 L-1 adipocytes were grown 
6–7 days post-confluence, and starved for 24 h in serum-free 
media containing FA-free BSA. Fatty acids were incubated in 
media containing FA-free BSA for two hours at 37°C in a 
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the COX enzymes by piroxicam (or other COX inhibitors,
data not shown) decrease FAS activity (Fig. 1); this effect
was reversed by admnistering mice EP receptor agonists.
These results demonstrate that a lipogenic and receptor-
mediated effect of PGE2, which coupled with its previ-
ously reported antilipolytic effects [11-14] likely favor
triglyceride storage. To further test direct effects of PGE2
manipulation in adipocytes, we used 3T3-L1 adipocytes
and used dietary polyunsaturated fatty acids (AA and
EPA) as well as pharmacological means (COX inhibition)
to modulate prostaglandin levels. Our goal was to test
whether changes in PGE2 levels led to parallel changes in
FAS activity or expression.
We report here dose-dependent increases in PGE2 levels
with AA and EPA treatments (p < 0.001) and, as expected,
AA exhibited a more potent induction of PGE2 secretion
versus EPA or control. Very limited information exists in
the literature regarding physiological levels of EPA, but
they are unlikely to approach those of AA due to large dif-
ference in their levels in membrane phospholipids. Stud-
ies conducted on postmenopausal women fed fish oil
found the EPA levels of plasma lipids was 750 μM [36,37].
Our dose response studies indicate that despite the clearly
powerful effect of AA in increasing PGE2 (compared to
EPA), the latter was also able to significantly elevate PGE2
levels especially at the 200 and 500 uM doses. Doses at
500 uM and above visibly impacted cell viability and mor-
phology (data not shown). Based on the manufacturer's
information for cross-reactivity (and confirmed in our
laboratory), the assay also detects PGE3 (cross reactivity
with PGE2 antibody), which may explain at least in part
increased PGE2 levels with EPA. Although the binding
affinities of AA and EPA for both isoforms of COX are
equivalent (Km = 5 μM), COX-1 and -2 oxygenate EPA at
~10% and ~35%, respectively, compared to the rate for AA
when added exogenously to cultured cells. Compared to
AA, EPA is a poorer substrate for COX-1 in vivo[44]. Com-
plicating this issue further is the fact that very little is
known concerning the actions of PGE3 and its subsequent
down stream signaling [42]. Studies in NIH 3T3 fibrob-
lasts found that PGE3 activated the same signaling path-
ways as PGE2, but with much less efficiency [3]. This
would imply that high levels of PGE3 might duplicate the
actions of PGE2, suggesting there would be a point of
diminishing returns with EPA supplementation and thus
the importance of using appropriate low doses for experi-
mentation and supplementation. It is also possible that
PGE3 may bind to EP receptors with affinities that differ
significantly from PGE2 [42], whereby the type and
number of receptors in adipocytes would also influence
the impact of EPA supplementation. While it is important
to point out these differences in PGE2 vs. PGE3 formation,
the main focus of this paper is primarily on the role of PG
and COX in modulating fatty acid synthesis.
Based on our dose response data, we chose to use interme-
diate dosage of 150 μM for the rest of our experiments.
This dose is also consistent with the findings of other stud-
ies [3,35], which demonstrated the ability to manipulate
secreted PGE2 by using EPA to compete with AA for incor-
poration into membrane phospholipids and subsequent
PG production.
PGE2 levels in the CI treatment group were significantly
lower than controls. Although the celecoxib preferentially
inhibits COX-2, no studies have shown whether it reduces
PGE2 levels in adipocytes. Most published evidence indi-
cates that inducible enzyme COX-2 is not expressed at
physiologically relevant levels in mature adipocytes under
normal conditions [31,45]. However, since we used a CI
Effect of exogenous PGE2 and COX inhibition on adipocyte PGE2 secretion (6A) and FAS activity (6B)Figure 6
Effect of exogenous PGE2 and COX inhibition on adi-
pocyte PGE2 secretion (6A) and FAS activity (6B). 
3T3 L-1 adipocytes were grown 6–7 days post-confluence, 
and starved for 24 h in serum free media containing FA free 
BSA. Treatment consisted of CI (1 μM), PGE2 (300 pM), and 
CI + PGE2. After 48 hours, 2 mL of media was removed and 
cells were scraped using 350 μL of sucrose buffer, sonicated, 
and centrifuged for 1 hour. Media and cytosolic extract were 
stored at -80° Media PGE2 levels and FAS activity were meas-
ured as described in the Materials and Methods. For all treat-
ments n = 8. Results represent the mean ± SEM. Values 
labeled with different letters are significantly different (p < 
0.05). Values with the same letters do not differ significantly.
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dose (1 μM) similar to that of IC50 (1.2 μM [46]), it is
plausible that constitutively expressed COX-1 activity was
also inhibited at this dose. Using FAS as a marker of adi-
pocyte lipogenesis, our data showed decreases in FAS
activity with the CI treatment. In agreement with our find-
ing, another study also showed that a non-specific COX
inhibitor, aspirin, also decreases lipogenesis or levels of
triacylglycerols in adipocytes [31].
The overall comparison of PGE levels for the AA, EPA, and
AA + EPA treatment groups correlated well with previ-
ously published data measuring tissue concentrations of
these fatty acids in mice fed diets supplemented with these
fatty acids, although the end points measured and experi-
mental models were different in our study compared to
those reported [33,40,47].
Treatment of adipocytes with either EPA or AA elicited sig-
nificant reductions in FAS mRNA compared to control,
consistent with previously reported inhibition of FAS
message by PUFA (36) in a degree of unsaturation and
chain length-dependent manner [17,48]. Therefore, regu-
lation of FAS expression in adipocytes by PUFA is inde-
pendent of changes in prostaglandin levels. Alternatively,
PG could be directly controlling FAS gene expression via a
receptor-mediated mechanism. Such opposing effects
may be explained by direct transcriptional effects of EPA
and AA on the FAS gene. Indeed, this theory is in line with
results from Deng et al. showing that degree of unsatura-
tion correlated highly with suppression of the SREBP-1c
promoter [39], the main transcription factor regulating
FAS and other lipogenic genes. However, it is worth not-
ing that since mRNA stability was not measured in these
experiments, it is also possible that increased stability was
responsible for the discrepancy between decreased FAS
mRNA expression and small changes in FAS activity in
response to PUFA treatments. It is also possible that this
discrepancy is due to a longer half-life of the FAS protein
such that we were unable to detect changes in enzyme
activity within our treatment times (24–48 hours).
Indeed, previous studies have shown that changes in FAS
mRNA half-life depend on cell culture treatments and
state of differentiation [49,50]. Another possibility is that
PGE2 treatments stimulate leptin secretion (as previously
documented Fain et al [15]) and elevated leptin levels
may subsequently decrease lipogenesis [51]. Thus,
decreased FAS expression may indirectly reflect effects of
PGE2 mediated by leptin [52,53]. Unfortunately, due to
the very low levels of leptin secretion in 3T3-L1, we were
not able to assess regulation of leptin in these cells. Addi-
tional possible mechanisms may involve the antithetic
actions of the EP receptors. Long et al. investigated the
role of COX mediated products of AA metabolism on reg-
ulation of glucose transporter 4 (GLUT 4). They found
that a 50-fold increase in endogenous PGE2 or exposure to
10 μM exogenous PGE2 resulted in an increase in cAMP
concentrations, consistent with activation of the EP2/EP4
receptor [54]. Additionally, studies using the specific
COX-2 inhibitor NS-398 on cortical collecting duct cells
found that NS-398 treatment increased EP3 and EP4 recep-
tor expression 3-fold [55]. Although the concentration of
exogenous PGE2 added in our treatments was much lower,
preliminary gene expression studies demonstrate that
celecoxib also influenced the expression of EP receptors
(specifically EP4, data not shown), which may differ from
effects of aspirin or other non-specific COX inhibitors. An
increase in EP4 receptors and the resulting increase in
cAMP would activate a pathway that would oppose the
decrease in cAMP responsible for the PGE2 mediated
decrease in lipolysis. Further work with EP receptor con-
centration and mechanism of action is necessary to delin-
eate the exact role of each receptor in regulating adipocyte
metabolism.
One surprising finding is that PGE2 recapitulated the
decrease of FAS activity and expression by COX inhibition
but that combined PGE2 and celecoxib treatments further
decreased FAS. These results may be due to and compli-
cated by changes in EP receptor expression and signaling
with PGE2 addition. It is also possible that the pathways
mediating PGE2 effects via its receptors are different from
those affected by COX inhibition. Further, COX inhibi-
tion was more potent than EPA in reducing FAS, possibly
due to higher levels of the two PGE isoforms in the pres-
ence of EPA compared to control.
Overall, our studies demonstrated the ability to pharma-
cologically decrease production of PGE2 using the selec-
tive COX-2 inhibitor celecoxib, which resulted in a
significant reduction in lipogenic enzyme activity. The use
of EPA was also shown to result in lower production of
PGE2 when compared to AA treatment. FAS mRNA expres-
sion was decreased by FA treatment in a manner similar to
the PUFA effects seen in the liver [16,27,28]. Given that
SREBP1c, an insulin responsive transcription factor, medi-
ates PUFA regulation of hepatic lipogenic genes, it is pos-
sible that PUFA regulation of adipocyte metabolism
modulates insulin sensitivity. Indeed, in the absence of
insulin, our cells expressed significantly higher PGE2 lev-
els than in the presence of insulin (data not shown).
Low PGE2 levels led to decreased lipogenesis and thus a
reduction in PGE2 levels would result in less inhibition of
lipolysis, which coupled with reported antilipogenic
effects of EPA and other polyunsaturated fatty acids would
still favorably impact adipose tissue levels and result in
decreased adiposity.
Further experimentation is required to determine the
mechanism of action of celecoxib and EPA versus PGE2 in
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adipose tissue. Additional data on the receptor affinities
and actions of PGE3, although difficult to approach at this
time given the lack of data in this area, are necessary in
order to understand the mechanism mediating EPA and
PGE3 effects on lipid metabolism.
This study also brings to light the need for further studies
on the function and impact of PGE3 in adipocytes to
determine if it does in fact elicit the same responses as
PGE2. If this is the case, then it may indicate a point of
diminishing benefit and the need to specify a consump-
tion range instead of recommending minimum consump-
tion levels. Understanding the mechanisms involved with
EPA metabolism takes on further importance with the
FDA move to allow qualified health claims for omega-3
fatty acids [56], as this will most certainly bring more
attention to these fatty acids and increase their consump-
tion even further.
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